ABSTRACT
Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency ((153)Sm-EDTMP and (89)Sr-Cl2) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries ((186)Re-HEDP, (117)Snm-DTPA and (223)Ra-Cl2). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each radiopharmaceutical. The dosimetry data can be used to individualise and further improve the treatment for each patient. Dosimetry for radionuclide therapy of bone metastases is feasible and can be performed in a routine clinical practice.
Subject(s)
Bone Neoplasms/radiotherapy , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/therapeutic use , Radiotherapy Planning, Computer-Assisted/methods , Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Humans , Pain/radiotherapy , Palliative Care , Phosphorus Radioisotopes/administration & dosage , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/pharmacokinetics , Radiotherapy Planning, Computer-Assisted/statistics & numerical data , Radium/administration & dosage , Rhenium/administration & dosage , Samarium/administration & dosage , Strontium Radioisotopes/administration & dosage , Tin Radioisotopes/administration & dosageABSTRACT
Using a standard quantity of Re-186 HEDP, for therapy of osseous metastases from carcinoma of the breast, Palmedo and associates reported leukocyte and thrombocyte responses at 4 and 8 weeks. These were analyzed by dividing results into categories, based on the numeric initial values. Thrombocytes at 8 weeks exceeded pretreatment values in 10 of 18 cases. This "over-rebound" was also found in 7 of 19 leukocyte responses. The ability to predict thrombocyte-leukocyte response, in most cases, was linked to the initial hematologic values. If coupled with data on the status of bone marrow, this may allow the quantity of therapeutic radiopharmaceutical used to be increased or decreased without irreversibly compromising hematopoietic responses.
Subject(s)
Blood Platelets/radiation effects , Bone Neoplasms/secondary , Carcinoma/secondary , Etidronic Acid/therapeutic use , Leukocytes/radiation effects , Leukopenia/classification , Organometallic Compounds/therapeutic use , Radiopharmaceuticals/therapeutic use , Rhenium/therapeutic use , Thrombocytopenia/classification , Tin Radioisotopes/therapeutic use , Bone Marrow/radiation effects , Bone Neoplasms/radiotherapy , Breast Neoplasms/pathology , Carcinoma/radiotherapy , Etidronic Acid/administration & dosage , Female , Follow-Up Studies , Forecasting , Humans , Leukocyte Count , Leukopenia/physiopathology , Organometallic Compounds/administration & dosage , Platelet Count , Radiopharmaceuticals/administration & dosage , Rhenium/administration & dosage , Thrombocytopenia/physiopathology , Tin Radioisotopes/administration & dosageSubject(s)
Humans , Child , Adult , Middle Aged , Gastroesophageal Reflux , /administration & dosage , Radiopharmaceuticals , Hydrogen-Ion Concentration , Nuclear Medicine , Tin Radioisotopes/administration & dosage , Tin Radioisotopes , Gastroesophageal Reflux/diagnosis , Esophageal Motility DisordersABSTRACT
Com a finalidade de produzir um agente hepático coloidal liofilizado marcado com 99mTc, preparou-se o Sn-Coloidal-99mTc. Determinaram-se a pureza radioquímica e estabilidade do produto marcado com 99mTC por cromatografia em papel e metanol 85% como solvente, obtendo-se rendimentos de marcaçäo superiores a 95%. Estudos comparativos de biodistribuiçäo em ratos Wistar foram feitos com Estanho Coloidal-Estanho Coloidal-99mTc e Enxofre Coloidal-99mTc, verificando-se em ambos os produtos que a captaçäo pelo fígado foi superior a 90%
